Beta Bionics (NASDAQ:BBNX) Price Target Cut to $24.00 by Analysts at Leerink Partners

Beta Bionics (NASDAQ:BBNX) had its price target lowered by Leerink Partners from $25.00 to $24.00 in a research note released on Wednesday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

BBNX has been the topic of several other reports. Bank of America lowered Beta Bionics from a “buy” rating to a “neutral” rating in a research report on Friday, January 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Beta Bionics in a report on Friday, March 27th. Stifel Nicolaus lowered their price objective on Beta Bionics from $22.00 to $20.00 and set a “buy” rating for the company in a research report on Wednesday. Wall Street Zen downgraded shares of Beta Bionics from a “hold” rating to a “sell” rating in a research report on Sunday, March 29th. Finally, Lake Street Capital set a $20.00 price target on shares of Beta Bionics in a research note on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Beta Bionics has an average rating of “Moderate Buy” and a consensus target price of $22.00.

Beta Bionics Price Performance

Shares of BBNX opened at $12.20 on Wednesday. The company has a 50-day simple moving average of $11.55 and a two-hundred day simple moving average of $19.92. The firm has a market capitalization of $543.63 million, a PE ratio of -8.08 and a beta of 5.06. Beta Bionics has a one year low of $8.80 and a one year high of $32.71.

Beta Bionics (NASDAQ:BBNX) last posted its earnings results on Tuesday, April 21st. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.04. Beta Bionics had a negative return on equity of 22.55% and a negative net margin of 60.27%.The firm had revenue of $27.63 million for the quarter. Analysts expect that Beta Bionics will post -1.96 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Beta Bionics during the first quarter valued at $95,000. Goldman Sachs Group Inc. purchased a new stake in shares of Beta Bionics in the first quarter worth $715,000. Woodline Partners LP bought a new position in shares of Beta Bionics during the first quarter valued at $1,530,000. Strs Ohio bought a new position in shares of Beta Bionics during the first quarter valued at $29,000. Finally, Rhumbline Advisers purchased a new position in shares of Beta Bionics in the 1st quarter worth about $158,000.

Key Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Raised FY‑2026 revenue guidance to $131M–$136M and increased gross‑margin outlook to 57.5%–59.5%, signaling stronger unit economics and margin expansion ahead. Beta Bionics projects $131M-$136M 2026 revenue and raises gross margin outlook to 57.5%-59.5%
• Positive Sentiment: Q1 showed strong sales growth (≈57% year‑over‑year reported in company commentary) and an EPS beat: reported loss of $0.49 vs. consensus ‑$0.53, highlighting improving operational leverage. Beta Bionics Inc (BBNX) Q1 2026 Earnings Call Highlights: Strong Sales Growth Amid Operational …
• Neutral Sentiment: Company released the full Q1 earnings presentation and earnings‑call transcript — useful for investors assessing cadence of product adoption and margin drivers. Beta Bionics, Inc. (BBNX) Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Two sell‑side firms lowered price targets (Leerink: $25→$24; Stifel: $22→$20) but retained Outperform/Buy ratings — indicates continued analyst confidence but a pull‑back in near‑term valuation expectations. Benzinga coverage of analyst price target changes
• Negative Sentiment: Zacks flagged a revenue miss headline despite the EPS beat (company reported $27.63M for Q1), which may fuel short‑term selling and skepticism about top‑line momentum. Beta Bionics, Inc. (BBNX) Reports Q1 Loss, Misses Revenue Estimates

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.